John H. Rex, MD

Chief Medical Officer, F2G Ltd. · Operating Partner, Advent Life Sciences · Adjunct Professor of Medicine, McGovern Medical School

I am a physician and drug developer with more than 30 years of development and policy
experience focused on antimicrobial agents. My experience includes moving
antifungal and antibacterial agents from preclinical development thru all
development phases in the context of (a) academic positions (NIAID, University
of Texas-Houston), (b) VP-level roles at a pharmaceutical multinational
(AstraZeneca), (c) board-level roles in in biotech companies (F2G, Ltd.;
Adenium Biotech ApS), (d) Expert-in-Residence at Wellcome Trust, (e) Chief
Strategy Officer for CARB-X, and (f) an Operating Partner role with Advent Life
Sciences. The first 15 years of my career focused on medical mycology and
spanned susceptibility testing methods, in vitro-in vivo translational studies,
and clinical trials. More recently, my work has broadened to include advancing
novel regulatory and reimbursement paradigms for antimicrobial agents, founding
of the New Drugs for Bad Bugs (ND4BB) program of Europe’s Innovative Medicines
Initiative (IMI), and leadership of an antifungal-focused biotech company. 

Click here to see my LinkedIn profile. 

Using ideas to connect, create, and inspire

Scroll to Top